Limits...
Survival prognostic factors in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy treatment: analysis from a single oncological center.

Graziosi L, Marino E, De Angelis V, Rebonato A, Donini A - World J Surg Oncol (2016)

Bottom Line: The aim of our study is to analyze survival, treatment-related morbidity, and safety in our experience of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.Univariate and multivariate analyses were done, and Cox's proportional hazard model was used to identify significant factors.Pre-operative parameters could be evaluated to choose patient who could benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

View Article: PubMed Central - PubMed

Affiliation: Department of General and Emergency Surgery, Santa Maria della Misericordia Hospital, University of Perugia, Via Dottori, 06132, Perugia, Italy.

ABSTRACT

Background: The aim of our study is to analyze survival, treatment-related morbidity, and safety in our experience of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Methods: Sixty-four patients were treated. Survival curves were calculated according to the Kaplan-Meier method. Univariate and multivariate analyses were done, and Cox's proportional hazard model was used to identify significant factors.

Results: Global 5-year overall survival was 55%. Overall survival was also evaluated according to neutrophils to lymphocytes ratio and neutrophils to platelets ratio. Overall survival according to pre-operative serum albumin level shows a difference in the two groups (P < 0.05). We observed minor or no adverse events in 53 cases (89.8%), while 3 patients (5.1%) showed a grade III-IV complication and 3 post-operative deaths (5.1%). Post-operative complication also influenced overall survival; patients in whom a minor complication occurred had a 3-year overall survival (OS) of 62% vs. a 3-year OS of 28% in patients who underwent a major complication (P < 0.1).

Conclusions: Hyperthermic intraperitoneal chemotherapy (HIPEC) could be a valid and feasible option for selected patients affected by gastrointestinal malignancies' peritoneal carcinomatosis. Pre-operative parameters could be evaluated to choose patient who could benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

No MeSH data available.


Related in: MedlinePlus

Overall survival according to serum albumin level; P < 0.05
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4815060&req=5

Fig6: Overall survival according to serum albumin level; P < 0.05

Mentions: However, OS according to pre-operative serum albumin level (Fig. 6) shows a difference in the two groups with a 5-year OS in the higher group of 70 % vs. a 5-year OS of 38 % in the lower group (P < 0.05).Fig. 6


Survival prognostic factors in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy treatment: analysis from a single oncological center.

Graziosi L, Marino E, De Angelis V, Rebonato A, Donini A - World J Surg Oncol (2016)

Overall survival according to serum albumin level; P < 0.05
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4815060&req=5

Fig6: Overall survival according to serum albumin level; P < 0.05
Mentions: However, OS according to pre-operative serum albumin level (Fig. 6) shows a difference in the two groups with a 5-year OS in the higher group of 70 % vs. a 5-year OS of 38 % in the lower group (P < 0.05).Fig. 6

Bottom Line: The aim of our study is to analyze survival, treatment-related morbidity, and safety in our experience of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.Univariate and multivariate analyses were done, and Cox's proportional hazard model was used to identify significant factors.Pre-operative parameters could be evaluated to choose patient who could benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

View Article: PubMed Central - PubMed

Affiliation: Department of General and Emergency Surgery, Santa Maria della Misericordia Hospital, University of Perugia, Via Dottori, 06132, Perugia, Italy.

ABSTRACT

Background: The aim of our study is to analyze survival, treatment-related morbidity, and safety in our experience of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Methods: Sixty-four patients were treated. Survival curves were calculated according to the Kaplan-Meier method. Univariate and multivariate analyses were done, and Cox's proportional hazard model was used to identify significant factors.

Results: Global 5-year overall survival was 55%. Overall survival was also evaluated according to neutrophils to lymphocytes ratio and neutrophils to platelets ratio. Overall survival according to pre-operative serum albumin level shows a difference in the two groups (P < 0.05). We observed minor or no adverse events in 53 cases (89.8%), while 3 patients (5.1%) showed a grade III-IV complication and 3 post-operative deaths (5.1%). Post-operative complication also influenced overall survival; patients in whom a minor complication occurred had a 3-year overall survival (OS) of 62% vs. a 3-year OS of 28% in patients who underwent a major complication (P < 0.1).

Conclusions: Hyperthermic intraperitoneal chemotherapy (HIPEC) could be a valid and feasible option for selected patients affected by gastrointestinal malignancies' peritoneal carcinomatosis. Pre-operative parameters could be evaluated to choose patient who could benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

No MeSH data available.


Related in: MedlinePlus